-
公开(公告)号:US20190192549A1
公开(公告)日:2019-06-27
申请号:US16185258
申请日:2018-11-09
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: MASATO YOSHIKAWA , Morihisa Saitoh , Taisuke Kato , Yayoi Yoshitomi , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Yusuke Sasaki , Masanori Okaniwa , Tsuneo Oda , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Shumpei Murata , Atsutoshi Okabe , Yoshihisa Nakada , Michiyo Mochizuki , Brian Scott Freeze , Taisuke Tawaraishi , Yasufumi Wada , Paul D. Greenspan
IPC: A61K31/7084 , A61P35/00 , A61K47/68 , A61K31/7076
CPC classification number: A61K31/7084 , A61K31/7076 , A61K47/6807 , A61P35/00 , C07H21/00 , C07H21/02
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
-
公开(公告)号:US09776962B2
公开(公告)日:2017-10-03
申请号:US14898633
申请日:2014-08-08
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Jumpei Aida , Yayoi Yoshitomi , Yuko Hitomi , Naoyoshi Noguchi , Yasuhiro Hirata , Hideki Furukawa , Akito Shibuya , Koji Watanabe , Yasufumi Miyamoto , Tomohiro Okawa , Nobuyuki Takakura , Seiji Miwatashi
IPC: C07D211/34 , C07D211/22 , C07D213/30 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D413/14
CPC classification number: C07D211/34 , C07D211/22 , C07D213/30 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D413/14
Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.
-